United Kingdom (UK)
Recombinant monoclonal antibody to IL-17. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma MCAF5352A (Afasevikumab).
Alternative Name(s) of Target: IL17; IL-17A; IL17A; CTLA8; Interleukin-17A; IL-17A; Cytotoxic T-lymphocyte-associated antigen 8; CTLA-8; IL17F; IL-17F; Interleukin-17F; IL-17F; Cytokine ML-1; IL-17AA; IL-17AF; IL-17FF
Immunogen: The original antibody was produced by immunizing HuMab® mice with human IL-17.
Specificity: This antibody is specific for human IL-17A and human IL-17F. It also binds their respective dimers — IL-17AA, IL-17AF, and IL-17FF.
Application Notes: This antibody successfully completed phase I clinical trials (Mitra et al., 2014; PMID: 25398489). The pharmacokinetics of this antibody and the post-dose levels of IL-17AA and IL-17FF in healthy were assessed as part of the phase I study (Peng et al., 2018; PMID: 30547287). The crystal structure of the Fab version of this antibody was resolved, and its binding kinetics (KD) was measured at 7.78 ± 0.23 pM. Furthermore, alterations to the antibody's aromatic residues in its binding site and their effect on binding kinetics were assessed (Tilegenova et al., 2020; PMID: 31779513).
Antibody first published in: PMID: